saving life through targeted therapies

Sauvie is a mission-driven biotechnology company with a focus to discover, develop and deliver innovative, highly targeted single-domain antibody based therapies that harness proven disease pathways.

Latest News

Sauvie Inc. Enters into an Exclusive Worldwide License Agreement to Develop and Commercialize a Nanobody-based NK Cell Engager

SHORT HILLS, N.J., Oct. 24, 2022/PRNewswire/ – Sauvie Inc. (the “Company”), a mission-driven biopharmaceutical company focused on sustainably building an immuno-oncology company, today announced Sauvie’s subsidiary, Sauvie BiKE LLC, has entered into an exclusive license agreement with Rutgers, The State University of New Jersey (“Rutgers”) for the development and worldwide commercialization rights of a bi-specific natural killer (NK) cell engager technology in the field of oncology.

Highly targeted therapies to save life.